SLS:NSD-Sellas Life Sciences Group Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 1.08

Change

-0.05 (-4.42)%

Market Cap

USD 0.09B

Volume

1.07M

Analyst Target

USD 8.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-1.53 (-0.30%)

USD 123.21B
REGN Regeneron Pharmaceuticals Inc

-13.46 (-1.98%)

USD 76.39B
ARGX argenx NV ADR

-3.01 (-0.49%)

USD 37.97B
ALNY Alnylam Pharmaceuticals Inc

-8.81 (-3.48%)

USD 31.94B
ONC BeiGene, Ltd.

-3.69 (-1.39%)

USD 28.70B
RPRX Royalty Pharma Plc

+0.39 (+1.18%)

USD 18.65B
SMMT Summit Therapeutics PLC

-0.30 (-1.49%)

USD 17.01B
UTHR United Therapeutics Corporatio..

-8.82 (-2.73%)

USD 14.37B
INCY Incyte Corporation

-2.01 (-3.24%)

USD 14.22B
MRNA Moderna Inc

-0.90 (-2.59%)

USD 13.74B

ETFs Containing SLS

ZMT:CA BMO S&P/TSX Equal Weight .. 5.98 % 0.61 %

+1.36 (+2.05%)

CAD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.85% 75% C 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.85% 75% C 76% C+
Trailing 12 Months  
Capital Gain 2.86% 77% C+ 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.86% 76% C+ 55% F
Trailing 5 Years  
Capital Gain -37.57% 58% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -37.57% 58% F 23% F
Average Annual (5 Year Horizon)  
Capital Gain 2,048.30% 97% N/A 98% N/A
Dividend Return 2,048.30% 97% N/A 98% N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 11,400.94% 3% F 2% F
Risk Adjusted Return 17.97% 74% C 51% F
Market Capitalization 0.09B 47% F 38% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.